



Jean-Marie Michot

MD

## General background

Jean-Marie Michot is a full-time medical internist at Gustave Roussy. He was first trained in Normandy at the University of Rouen until 2004. He began his training in Paris in 2004 at the University Paris Diderot and obtained a Master 2 specialization in Immunology from the Pasteur Institute of Paris in 2009. He is certified in Internal Medicine and received the Silver Medal from the Faculty of Medicine of Paris in 2010. Dr. Michot is affiliated with the Department of Internal Medicine and Clinical Immunology at University Paris-South Hospital since 2010. He joined the Hematology Unit of Gustave Roussy in 2013 where he developed phase 1 hematology clinical trials with Vincent Ribrag and Stéphane De Botton.

He had a focus for new treatments in lymphoproliferative disorders. His wish is to advance new therapies, and to develop personalized medicine approaches. He aims to improve the management of immunological related adverse events of new immune-checkpoint inhibitors.

## EARLY CLINICAL TRIALS EXPERTISE

### ORAL PRESENTATIONS

#### ICML 2017

- Phase Ib study of CC-122 in combination with obinutuzumab (GA101): relapsed or refractory (R/R) patients with B-cell non-Hodgkin lymphoma (NHL)

#### TAT 2017

- Phase IB study of CC-122 and obinutuzumab in relapsed or refractory diffuse large B-cell lymphoma and indolent non-Hodgkin lymphoma (oral)

### PUBLICATIONS

- Armand P, Shipp MA, Ribrag V, **Michot JM**, Zinzani PL, Kuruville J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. *J Clin Oncol*. 2016 Jun 27. pii: JCO673467 [Epub ahead of print]

- Michot JM**, Mazon R, Dercle L, Ammari S, Canova C, Marabelle A, Rose S, Rubin E, Deutsch E, Soria JC, Ribrag V, Levy A. Abscopal effect in a Hodgkin lymphoma patient treated by an anti-programmed death 1 antibody. *Eur J Cancer*. 2016;66:91-4.

- Thijssen R, Ter Burg J, Garrick B, van Bochove GG, Brown JR, Fernandes SM, Rodriguez MS, **Michot JM**, Hallek M, Eichhorst B, Reinhardt HC, Bendell J, Derks IA, van Kampen RJ, Hege K, Kersten MJ, Trowe T, Filvaroff EH, Eldering E, Kater AP (2016) Dual TORC/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. *Blood*. 2016;128(4):574-583.

- Aftimos P, Rolfo C, Rottey S, Offner F, Bron D, Maerevoet M, Soria JC, Moshir M, Dreier T, Van Rompaey L, **Michot JM**, Silence K, Hultberg A, Gandini D, de Haard H, Ribrag V, Peeters M, Thibault A, Leupin N, Awada A. Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies. *Clin Cancer Res*. 2017 Nov 1;23(21):6411-6420.

- Zinzani PL, Ribrag V, Moskowitz CH, **Michot JM**, Kuruville J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. *Blood*. 2017 Jul 20;130(3):267-270.